Otsuka (OTCMKTS:OTSKY) Sees Strong Trading Volume – Should You Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares saw an uptick in trading volume on Monday . 26,906 shares changed hands during trading, a decline of 31% from the previous session’s volume of 38,936 shares.The stock last traded at $34.10 and had previously closed at $32.97.

Analyst Upgrades and Downgrades

OTSKY has been the subject of a number of analyst reports. The Goldman Sachs Group downgraded Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Otsuka has an average rating of “Hold”.

Otsuka Price Performance

The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average price of $34.41 and a 200 day moving average price of $32.53. The stock has a market capitalization of $35.54 billion and a price-to-earnings ratio of 13.96.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. The company had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, equities research analysts expect that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.